CDH18 and breast carcinoma: Remarkably, the twofold increase in the median PFS between CDH18-positive and CDH18-negative patients with WD/DDLS is comparable in magnitude to the twofold increase in the duration of response in HR + , Her2− breast cancer patients treated with letrozole and palbociclib.